Adalimumab in the treatment of arthritis

Therapeutics and Clinical Risk Management

Volumn 3, Issue 1, 2007, Pages 133-148

  Mease, Philip J ^a  

^a Seattle Rhumatology Associates   (United States)

Author keywords

Adalimumab; Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis; TNF antagonists

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; CORTICOSTEROID; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACCIDENTAL INJURY; ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BACKACHE; BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNOVIAL FLUID LEVEL; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEMATURIA; HISTOPLASMOSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOREGULATION; INFECTION; INFECTION RISK; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LISTERIOSIS; LONG TERM CARE; LUNG ASPERGILLOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NEUROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PNEUMOCYSTIS PNEUMONIA; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; SINUSITIS; SOLID TUMOR; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 34247552202     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.1.133     Document Type: Review

References (74)

1. Anderson PJ. 2005. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum, 34(5 Suppl 1):19-22.
2. Antoni C, Kavanaugh A, Kirkham B, et al. 2003. The one year results of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum, 48:S265.
3. Antoni C, Kavanaugh A, Kirkham B, et al. 2005. Sustained benefits of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 52:1227-36.
4. Antoni C, Krueger GG, de Vlam K, et al. 2005. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis, 64:1150-7.
5. Askling J, Fored CM, Brandt L, et al. 2005. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis, 64:1421-6.
6. Barrera P, Joosten LA, den Broeder AA, et al. 2001. Effects of treatment with a fully human anti-tumour necrosis factor monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF in patients with rheumatoid arthritis. Ann Rheum Dis, 60:660-9.
7. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-85.
8. Brandt J, Khariouzov A, Listing J, et al. 2003. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum, 48:1667-75.
9. Braun J, Bollow M, Neure L, et al. 1995. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum, 38:499-505.
10. Braun J, Brandt J, Listing J, et al. 2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet, 359:1187-93.
11. Braun J, Brandt J, Listing J, et al. 2003. Long-term efficacy and safety of infliximab in the treatment ofankylosing spondylitis. Arthritis Rheum, 48:2224-33.
12. Breedveld FC, Weisman MH, Kavanaugh AF, et al. 2005. The efficacy and safety of adalimumab (Humira®) plus methotrexate vs. adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis: 1- and 2-year results of the PREMIER study [abstract]. Ann Rheum Dis, 64:60.
13. Breedveld FC, Weisman MH, Kavanaugh AF, et al; for the PREMIER investigators. 2006. The PREMIER Study: combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in methotrexate-naYve patients with early, aggressive rheumatoid arthritis. Arthritis Rheum, 54:26-37.
14. Brennan FM, Browne KA, Green PA, et al. 1997. Reduction of serum matrix metalloproteinase I and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-a (cA2) therapy. Br J Rheumatol, 36:643-50.
15. Burmester GR, Saez IM, Malaise M, et al. 2004. Efficacy and safety of adalimumab in European clinical practice: the ReAct Trial [abstract]. Ann Rheum Dis, 63(Suppl 1):90.
16. Burmester GR, Monteagudo Sáez I, Malaise MG, et al. 2005. Adaliniumab (Humira®) is effective and safe in treating rheumatoid arthritis (RA) in real-life clinical practice: 1-year-results of the ReAct study [abstract]. Arthritis Rheum, 52(Suppl):S541-2.
17. Burmester G, Mease PJ, Dijkmans BAC, et al. 2006. Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis. Ann Rheum Dis, 65(Suppl II): 181-2.
18. Catrina AI, Lampa J, Ernestam, et al. 2002. Anti-tumour necrosis factor (TNF)-a therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford), 41:484-9.
19. Catrina AI, af Klint E, Ernestam S, et al. 2006. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum, 54:76-81.
20. Choy EH, Panayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 344:328-46.
21. den Broeder AA, Joosten LAB, Saxne T, et al. 2002. Long term anti-tumour necrosis factor a monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis, 61:311-18.
22. Furst DE, Schiff MH, Fleischmann RM, et al. 2003. Efficacy and safety of the fully human anti-tumour necrosis factor-monoclonal antibody, and concomitant standard antirlicumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial ofAdalimumab in Rheumatoid Arthritis). J Rheumatol, 30:2563-71.
23. Geborek P, Bladstrom A, Turesson C, et al. 2005. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis, 64:699-703.
24. o) plus MTX or MTX alone [presentation 1178]. Ann Rheum Dis, 64(Suppl 1):295.
25. Gorman JD, Sack KE, Davis JC. 2002. Treatment ofankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med, 346:1349-56.
26. Heinzlef O, Alamowitch S, Sazdovitch V, et al. 2000. Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand, 101:36-40.
27. [HUMIRA PI] HUMIRA® (adalimumab) Prescribing Information. 2006. Abbott Laboratories, North Chicago, IL, 60064 USA. July 2006.
28. [HUMIRA PC] HUMIRA® (adalimumab) Summary of Product Characteristics. 2006. Abbott Laboratories, North Chicago, IL, 60064 USA.
29. Isomaki HA, Hakulmen T, Joutsenlahti U. 1978. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis, 31:691-6.
30. Kavanaugh A, Grenwald M, Zizic T, et al. 2002. Treatment with adalimumab (D2E7) does not affect normal immune responsiveness [abstract]. Arthritis Rheum, 45(Suppl 9):S132.
31. Keystone EC. 2005. Safety ofbiologic therapies - an update. J Rheumatol, 32 (Suppl):8-12.
32. Keystone E, Furst DE, Kavanaugh AF, et al. 2003. Subgroup analysis of radiographic progression in RA patients treated with adalimumab [abstract]. Ann Rheum Dis, 62(Suppl 1): 169.
33. Keystone E, Kavanaugh AF, Fischkoff S. 2003. Response to adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Ann Rheum Dis, 62(Suppl 1): 170.
34. Keystone EC, Kavanaugh AF, Perez JL, Spencer-Green GT. 2004. Adalimumab (Humira) plus methotrexate provides sustained improvements in physical function over 2 years in treatment of patients with rheumatoid arthritis [abstract]. Ann Rheum Dis, 64(Suppl 1):279.
35. Keystone EC, Kavanaugh AF, Sharp JT, et al. 2004a. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum, 50:1400-11.
36. Keystone EC, Kavanaugh AF, Sharp JT, et al. 2004b. Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 2 years of treatment with adalimumab (Humira) plus methotrexate [abstract]. Ann Rheum Dis, 64(Suppl 1):277.
37. Keystone EC, Kavanaugh AF, Sharp JT, et al. 2004c. Radiographic inhibition of structural damage sustained in patients with long-standing rheumatoid arthritis following 3 years of treatment with adalimumab (Humira) plus methotrexate [abstract]. Arthritis Rheum 50(Suppl):S189 (Poster 371).
38. Keystone E, Haraoui B, Bykerk VP. 2003. Role of adalimumab in patients with early versus late rheumatoid arthritis (RA) [abstract]. Clin Exp Rheumatol, 21(5 Suppl 31): S198-9.
39. Klareskog L, van der Heijdc D, de Jager JP, et al. 2004. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet, 363:675-81.
40. Lee SJ, Kavanaugh A. 2005. Adalimumab for the treatment of rheumatoid arthritis. Therapy, 2:13-21.
41. Lipsky PE, van der Heijde DM, St Clair EW, et al; the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 2000a. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med, 343:1594-602.
42. Lipsky PE, van der Heijde DM, St Clair EW, et al. 2000b. 102-wk clinical and radiologic results from the ATTRACT trial: a 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade®) in pis with active RA despite MTX [abstract]. Arthritis Rheum, 43:S269.
43. Magnano M, Robinson WH, Genovese MC. 2004. Demyelination and the use of TNF inhibition. Clin Exp Rheumatol, 22(5 Suppl 35):S134-40.
44. Maim R, St Clair EW, Breedveld F, et al. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet, 354:1932-9.
45. Mease P. 2005. TNF-α inhibitors in psoriatic arthritis. In: Gordon KB, Ruderman EM (eds). Psoriasis and psoriatic arthritis: an integrated approach. Springer-Verlag, Heidelberg, Germany, pp 223-34.
46. Mease PJ, Antoni CE. 2005. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis, 64(Suppl 11):08-82.
47. Mease PJ, Gladman DD, Ritchlin CT, et al; the ADEPT Study Group. 2005a. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. ADEPT. Arthritis Rheum, 52:3279-89.
48. Mease PJ, Gladman DD, Ritchlin CT, et al. 2005b. Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results ofADEPT [abstract]. Arthritis Rheum, 52(Suppl):S215.
49. Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet, 356:385-90.
50. Mease P, Kavanaugh A, Krueger G, et al. 2004. Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 trial. Arthritis Rheum, 50:S616.
51. Mease PJ, Ruderman EM, Kivitz AJ, et al. 2003. Continued efficacy and safety of etanercept (ENBREL®) in patients with psoriatic arthritis and psoriasis. Arthritis Rheum, 48(9S): (Abstract 343)S169.
52. Mease P, Sharp J, Ory P, et al. 2005. Inhibition ofjoint destruction in PsA with adalimumab: 48-week results of ADEPT [abstract]. Arthritis Rheum, 52(Suppl): S631.
53. Moreland LW, Baumgartner SW, Schiff MH, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med, 337:141-7.
54. Moreland LW, Schiff MH, Baumgartner SW, et al. 1999, Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med, 130:478-86,
55. O'Dell JR. 2002. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum, 46:283-5.
56. Partsch G, Steiner G, Lech BF, et al. 1997. Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol, 24:518-23.
57. Ritchlin C, Haas-Smith SA, Hicks D, et al. 1998. Patterns of cytokine production in psoriatic synovium. J Rheumatol, 25:1544-52.
58. Ritchlin CT, Mease PJ, Sasso EH. 2006. Correlation of skin and joint responses in psoriatic arthritis: ADEPT subanalysis. Poster presentation at the Spring Symposium of the European Academy of Dermatology and Venereology (EADV), February 9-12, 2006, Lapland, Finland.
59. Saxne T, Palladino MAJr, Heinegard D, et al. 1988. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum, 31:1041-5.
60. Schiff MH, Burmester GR, Kent J, et al. 2006. Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis, 65:889-94.
61. Schiff M, van de Putte LB, Breedveld FC, et al. 2003. Rates of infection in adalimumab rheumatoid arthritis clinical trials [abstract]. Ann Rheum Dis, 62(Suppl 1): 184.
62. Strand V, Weisman MH, Nichol MB, et al. 2003. Adalimumab improves health-related quality of life in rheumatoid arthritis patients [abstract no. 99]. Arthritis Rheum, 48(9 Suppl):S402.
63. Strand V, Chartash E, Sengupta N, et al. 2003. Improvement in health-related quality of life, health utility, and fatigue in patients with active rheumatoid arthritis (RA) on adalimumab (Humiraä, Abbott) therapy [abstract no. SAT0246]. Ann Rheum Dis, 62(Suppl 1):356.
64. Thomson BM, Mundy GR, Chambers TJ. 1987. Tumor necrosis factors a and b induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol, 138:775-9.
65. van der Heijde D, Landewe RBM, Keystone EC, et al. 2005. Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis. Arthritis Rheum, Suppl:S110 (Poster Presentation 207).
66. van der Heijde D, Dijkmans B, Geusens P, et al. 2005. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum, 52:582-91.
67. van der Heijde D, Kivitz A, Schiff MH, et al; the Adalimumab Trial Evaluating Long-term Efficacy and Safety in Ankylosing Spondylitis Study Group. 2006. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ATLAS). Arthritis Rheum, 54:2136-46.
68. van de Putte LBA, Salfeld J, Kaymakcalan Z. 2003. Adalimumab. In: Moreland LW, Emery P (eds). TNF-inhibition in the treatment of rheumatoid arthritis. London: Martin Dunitz, pp 71-93.
69. van de Putte LB, Atkins C, Malaise M, et al. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirlicumatic drug treatment has failed. Ann Rheum Dis, 63:508-16.
70. Weinblatt ME, Keystone EC, Furst DE, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody for the treatment of RA in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum, 48:35-45.
71. Weinblatt ME, Keystone EC, Furst DE, et al. 2004. The ARMADA trial: sustained efficacy and long-term safety of adalimumab (Humira) plus methotrexate over 3 years in patients with long-standing rheumatoid arthritis [abstract]. Ann Rheum Dis, 64(Suppl 1):295.
72. Weinblatt ME, Keystone EC, Furst DE, et al. 2005. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis in the ARMADA trial [abstract]. Arthritis Rheum, 52(Suppl):S563 (Poster 1497).
73. Weinblatt ME, Kremer JM, Bankburst AD, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 340:253-9.
74. Wells AF, Kupper H, Fischkiff S, et al. 2003. Injection site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials [abstract]. Ann Rheum Dis, 62(Suppl 1):411.